Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi platform
technology is designed to make immune cells more effective in
killing tumor cells, today announced that its clinical development
partners, AgonOx, Inc. and Providence Cancer Institute of Oregon,
have dosed their first patient in an Adoptive Cell Therapy clinical
trial.
This first-in-human trial is investigating the safety and the
potential for enhanced therapeutic benefit from the administration
of AgonOx’s AGX148 'double positive' (DP) CD8 tumor-infiltrating
lymphocytes (TIL) alone and in combination with Phio's PD-1
silencing PH-762 in patients with melanoma and other advanced solid
tumors. More information about this clinical trial is available at
clinicaltrials.gov. The clinical trial is one of two studies
cleared by the FDA which will utilize Phio’s lead product
candidate, PH-762.
The trial is being conducted at Providence Cancer Institute in
Portland, Oregon, by Principal Investigator Brendan Curti, M.D.,
medical oncologist and Robert W. Franz Endowed Chair for Clinical
Research at the Earle A. Chiles Research Institute, a division of
Providence. “Our institute has been at the leading edge of
immunotherapy clinical research including checkpoint immunotherapy,
novel co-stimulatory agents and cancer vaccines,” said Dr. Curti.
“Our vision of the future is to select and engineer immune cells
with enhanced abilities to attack tumors. We have a strong record
of accomplishment in translating laboratory ideas into clinical
practice. The work with Dr. Weinberg is another example of exciting
first-in-human translational science from our Institute and its
many ongoing collaborations.”
“TIL therapies hold the promise of clinical benefit in patients
with solid malignancies. This product is different from current TIL
therapies as we are selectively expanding the tumor-reactive T
cells and potentially increasing their potency by reducing PD-1
suppression,” said Andrew Weinberg, Ph.D., Founder and CSO of
AgonOx, Inc., and Judith Ann Hartmann Endowed Chair for the
Laboratory of Basic Immunology at the Earle A. Chiles Research
Institute.
“This is an important collaborative milestone between these
organizations in the advancement of treatments for solid tumors,”
said Robert Bitterman, President and CEO of Phio
Pharmaceuticals.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage
biotechnology company whose proprietary INTASYL™ RNAi technology is
designed to make immune cells more effective in killing tumor
cells. INTASYL is the only self-delivering RNAi technology focused
on immuno-oncology therapeutics. INTASYL drugs precisely target
specific proteins that reduce the body's ability to fight cancer,
without the need for specialized formulations or drug delivery
systems.
For additional information, visit the Company's website,
www.phiopharma.com.
About AgonOx, Inc.
AgonOx, Inc. is a privately held, Portland, OR-based
biotechnology company. The company was the first to identify and
expand tumor-reactive T cells using CD39 and CD103 (DP) CD8s. A
patented process that can also be used to identify tumor-reactive
TCRs. AgonOx is also developing a pipeline of novel immunotherapy
drugs targeting key regulators of the immune response to cancer.
For additional information, visit the company's website,
www.agonox.com.
About Providence Cancer Institute of Oregon
Providence Cancer Institute of Oregon, a part of Providence St.
Joseph Health, offers the latest in cancer services, including
diagnosis, treatment, prevention, education and support. Providence
is home to the Earle A. Chiles Research Institute, an
internationally renowned leader in the field of cancer
immunotherapy since 1993, where investigators lead numerous
clinical trials for patients with cancers of the breast, colon,
prostate, lung, esophagus, liver, pancreas, head and neck, ovary,
skin, blood and other conditions. Learn more at
Providence.org/ORcancer.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"intends," "believes," "anticipates," "indicates," "plans,"
"expects," "suggests," "may," "would," "should," "potential,"
"designed to," "will," "ongoing," "estimate," "forecast," "target,"
"predict," "could" and similar references, although not all
forward-looking statements contain these words. These statements
are based only on our current beliefs, expectations and assumptions
and are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Examples of forward-looking statements
include statements regarding the timing of the clinical trial with
AGX148 DP TIL alone and in combination with PH-762, as well as the
progress of, and data reported from, this clinical trial and the
therapeutic potential of AG148 DP TIL alone or in combination with
PH-762. Our actual results may differ materially from those
indicated in the forward-looking statements as a result of a number
of important factors, including, but not limited to, the impact to
our business and operations by inflationary pressures, rising
interest rates, recession fears, the development of our product
candidates, results from our preclinical and clinical activities,
our ability to execute on business strategies, our ability to
develop our product candidates with collaboration partners, and the
success of any such collaborations, the timeline and duration for
advancing our product candidates into clinical development, the
timing or likelihood of regulatory filings and approvals, the
success of our efforts to commercialize our product candidates if
approved, our ability to manufacture and supply our product
candidates for clinical activities, and for commercial use if
approved, the scope of protection we are able to establish and
maintain for intellectual property rights covering our technology
platform, our ability to obtain future financing, market and other
conditions and those identified in our Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q under the caption
"Risk Factors" and in other filings the Company periodically makes
with the SEC. Readers are urged to review these risk factors and to
not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. Phio does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release, except as
required by law.
Contact:Phio Pharmaceuticals Corp.Caitlin
Kontulisir@phiopharma.com
Bridge View MediaMichael
Adamsadams@bridgeviewmedia.com
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Phio Pharmaceuticals (NASDAQ:PHIO)
Historical Stock Chart
From Aug 2023 to Aug 2024